Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Lenacapavir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Recipient : Gilead Sciences
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Gilead Partners with Six Generic Makers to Expand HIV Prevention Access Globally
Details : The agreement aims to make and sell generic lenacapavir, subject to required regulatory approvals, in 120 high-incidence, resource-limited countries for HIV prevention.
Brand Name : Sunlenca
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 02, 2024
Lead Product(s) : Lenacapavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Recipient : Gilead Sciences
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Baricitinib
Therapeutic Area : Immunology
Study Phase : Approved
Sponsor : Eli Lilly
Deal Size : Undisclosed
Deal Type : Collaboration
Lilly, EVA Pharma Collaborate To Expand Baricitinib Access in Low-Income Nations
Details : The collaboration aims to expand access to Olumiant (baricitinib), an orally-administered, small-molecule, JAK inhibitor, in low- to middle-income countries.
Brand Name : Olumiant
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 04, 2024
Lead Product(s) : Baricitinib
Therapeutic Area : Immunology
Highest Development Status : Approved
Sponsor : Eli Lilly
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?
Reset All
